This segment focuses on the development and commercialization of innovative solutions for treating urothelial cancers, including both non-muscle invasive bladder cancer (NMIBC) and upper tract urothelial carcinoma (UTUC). Key products and candidates include JELMYTO® for UTUC and UGN-102 for low-grade NMIBC. Research and development efforts are directed towards improving intravesical drug delivery and enhancing therapeutic efficacy while minimizing systemic toxicity. The segment leverages the RTGel™ technology platform to provide sustained local drug exposure. Clinical trials are ongoing to evaluate the safety and efficacy of UGN-102 in various NMIBC subtypes, with the goal of providing patients with effective alternatives to surgery. Future opportunities include expanding the application of RTGel™ to other urologic malignancies and developing novel combination therapies.